Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Failure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver
Max Preti, Lena Schlott, David Lübbering, Daria Krzikalla, Anna-Lena Müller, Fenja A. Schuran, Tobias Poch, Miriam Schakat, Sören Weidemann, Ansgar W. Lohse, Christina Weiler-Normann, Marcial Sebode, Dorothee Schwinge, Christoph Schramm, Antonella Carambia, Johannes Herkel
Max Preti, Lena Schlott, David Lübbering, Daria Krzikalla, Anna-Lena Müller, Fenja A. Schuran, Tobias Poch, Miriam Schakat, Sören Weidemann, Ansgar W. Lohse, Christina Weiler-Normann, Marcial Sebode, Dorothee Schwinge, Christoph Schramm, Antonella Carambia, Johannes Herkel
View: Text | PDF
Research Article Hepatology

Failure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver

  • Text
  • PDF
Abstract

The liver is an immune-privileged organ that can deactivate autoreactive T cells. Yet in autoimmune hepatitis (AIH), autoreactive T cells can defy hepatic control and attack the liver. To elucidate how tolerance to self-antigens is lost during AIH pathogenesis, we generated a spontaneous mouse model of AIH, based on recognition of an MHC class II–restricted model peptide in hepatocytes by autoreactive CD4+ T cells. We found that the hepatic peptide was not expressed in the thymus, leading to deficient thymic deletion and resulting in peripheral abundance of autoreactive CD4+ T cells. In the liver, autoreactive CD4+ effector T cells accumulated within portal ectopic lymphoid structures and maturated toward pathogenic IFN-γ and TNF coproducing cells. Expansion and pathogenic maturation of autoreactive effector T cells was enabled by a selective increase of plasticity and instability of autoantigen-specific Tregs but not of nonspecific Tregs. Indeed, antigen-specific Tregs were reduced in frequency and manifested increased IL-17 production, reduced epigenetic demethylation, and reduced expression of Foxp3. As a consequence, autoantigen-specific Tregs had a reduced suppressive capacity, as compared with that of nonspecific Tregs. In conclusion, loss of tolerance and the pathogenesis of AIH were enabled by combined failure of thymic deletion and peripheral regulation.

Authors

Max Preti, Lena Schlott, David Lübbering, Daria Krzikalla, Anna-Lena Müller, Fenja A. Schuran, Tobias Poch, Miriam Schakat, Sören Weidemann, Ansgar W. Lohse, Christina Weiler-Normann, Marcial Sebode, Dorothee Schwinge, Christoph Schramm, Antonella Carambia, Johannes Herkel

×

Figure 1

Generation of Alb-iGP_Smarta mice and characterization of thymic and peripheral autoreactive CD4+ T cells.

Options: View larger image (or click on image) Download as PowerPoint
Generation of Alb-iGP_Smarta mice and characterization of thymic and per...
(A) Scheme of the Alb-iGP system. The CLIP sequence in the CD74 gene was replaced by the GP61–80 sequence, facilitating high occupancy of MHC II molecules and GP61–80 presentation. (B) Cre-mediated removal of a STOP cassette facilitates expression of the mutant CD74 molecule under Rosa26 promoter control. (C) GP61–80 expression levels in thymus and liver of Itgax-iGP_Smarta and Alb-iGP_Smarta mice, as determined by quantitative RT-PCR relative to the HPRT housekeeper gene expression. (D) Representative flow cytometry dot plots of antigen-specific I-A(b) GP66–77 tetramer–binding CD4+ T cells in thymus (top) or spleen (bottom) in C57BL/6 mice, Alb-iGP mice expressing the mutant CD74 molecule, Smarta mice expressing a transgenic T cell receptor recognizing the cognate GP61–80 peptide, Itgax-iGP_Smarta mice, or Alb-iGP_Smarta mice, featuring both presentation of the GP61–80 peptide and the cognate Smarta T cell receptor. (E) Thymic (top) and splenic (bottom) frequencies of I-A(b) GP66–77 tetramer–specific CD4+ T cells in C57BL/6, Alb-iGP, Smarta, Itgax-iGP_Smarta, or Alb-iGP_Smarta mice. Data are shown as the mean ± SEM (n = 4–12). *P < 0.05; ****P < 0.0001 (C, Mann-Whitney; E, ANOVA).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts